AS SODIUM SALT
ACIPHEX, RABEPRAZOLE SODIUM
Drug Patent Expiration and Exclusivity
|Active Ingredient||Form||Dosage||Drug Type||Application||Product|
|RABEPRAZOLE SODIUM||TABLET, DELAYED RELEASE; ORAL||10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**||DISCN||020973||001|
|RABEPRAZOLE SODIUM||TABLET, DELAYED RELEASE; ORAL||20MG||RX||020973||002|
EISAI INC’s ACIPHEX.
|US 5045552||Pyridine derivatives having anti-ulcerative activity
Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.
Exclusivity is marketing rights granted by the FDA to the EISAI INC.